---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-276161"
form_type: "8-K"
ticker: "ALKS"
cik: "0001520262"
company_name: "Alkermes plc."
filed_at: "2025-11-12T23:59:59+00:00"
generated_at: "2026-05-16T21:08:35.678057+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Alkermes' alixorexton meets dual primary endpoints in Phase 2 narcolepsy type 2 study

## Summary
- Alixorexton (10, 14, 18 mg) showed statistically significant improvements vs placebo on MWT and ESS at week 8.
- 14 mg and 18 mg doses achieved statistical significance on MWT (p<0.05); 18 mg dose on ESS (p<0.05).
- Drug was generally well tolerated; most common TEAEs were pollakiuria, insomnia, urinary urgency, dizziness, headache.
- No serious TEAEs, no safety signals in hepatic, renal, vitals, ECGs, or ophthalmic exams.
- Phase 3 program for narcolepsy type 1 and type 2 expected to initiate in Q1 2026.

## SEC filing metadata
- accession: 0001193125-25-276161
- form_type: 8-K
- ticker: ALKS
- cik: 0001520262
- company_name: Alkermes plc.
- filed_at: 2025-11-12T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1520262/000119312525276161/0001193125-25-276161-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1520262/000119312525276161/alks-20251112.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-276161
- JSON: https://secwatch.observer/filing/0001193125-25-276161.json
- Plain text: https://secwatch.observer/filing/0001193125-25-276161.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.